Jaguar Health Finalizes Highly Dilutive Financing Terms with $1.10 ELOC Floor and Forced Preferred Stock Redemption
JAGX sits 37% above its 52-week low of $2.53.
Summary
Jaguar Health has finalized critical terms for its dilutive financing agreements, setting a low floor price for equity sales and introducing forced redemption clauses for preferred stock that could lead to significant shareholder dilution.
Key Events · Financing and Capital Events · JAGX
-
ELOC Floor Price Set
The Equity Line of Credit (ELOC) agreement now specifies a floor price of $1.10 per share for sales to C/M Capital, well below the current market price.
-
Forced Preferred Stock Redemption
The Series P Preferred Stock agreement includes a new "Consequences of Triggering Events" clause, allowing C/M Capital to force redemption of their preferred shares into common stock at a defined floor price if the company breaches covenants or after three years.
-
ELOC Proceeds for Preferred Redemption
10% of the net proceeds from the ELOC will be used to redeem outstanding shares of Series P Preferred Stock.
-
Preferred Stock Proceeds Restricted
Proceeds from the Preferred Stock Private Placement are designated for working capital and general corporate purposes, explicitly excluding debt satisfaction, security repurchase, or litigation settlement.
Analysis · JAGX · Life Sciences
This filing provides definitive details for the previously announced highly dilutive financing agreements with C/M Capital. The Equity Line of Credit (ELOC) now includes a specific floor price of $1.10 for share sales, significantly below the current market price, indicating potential for substantial dilution if the stock declines. Furthermore, the Series P Preferred Stock agreement introduces a "Forced Redemption" clause, allowing C/M Capital to convert their preferred shares into common stock at a low floor price if the company breaches covenants or after three years, posing a significant risk of further dilution for common shareholders.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 42.6% of the 488 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.42%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $3.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $2.53 to $171.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.